Navigation Links
Biocept Announces Study to Isolate Circulating Tumor Cells from Blood
Date:12/3/2007

SAN DIEGO, Dec. 3 /PRNewswire/ -- Biocept, an emerging leader in biotechnology, is initiating a collaborative study with the University of Texas M.D. Anderson Cancer Center to investigate the ability to isolate circulating tumor cells (CTCs) in blood. The study will use Biocept's proprietary CEE(TM) (Cell Enrichment and Extraction) technology, designed to capture rare cells from a larger heterogeneous cell population. The focus of this study is ovarian cancer.

"This innovation in rare cell capture offers an enhanced opportunity to detect circulating ovarian cancer cells," says principal investigator Anil Sood, MD. "The goal is to provide more powerful tools to monitor the response to treatment, improve early detection and personalize prognosis for our patients."

The study has three goals: to optimize detection and isolation of circulating tumor cells (CTCs) in ovarian cancer patients, to quantify the levels of CTCs in patients with primary or recurrent ovarian cancer, and to compare gene profiles between CTCs and primary tumor specimens. The findings could provide valuable insight towards treatment planning and identification of novel biologic targets.

"We hope that our ability to isolate and quantify circulating tumor cells will improve cancer detection and treatment by giving physicians valuable information early in the disease course," says Gordon Janko, president and CEO of Biocept.

About Ovarian Cancer

Ovarian cancer forms in tissues of the ovary (one of a pair of female reproductive glands in which the ova, or eggs, are formed). Most ovarian cancers are either ovarian epithelial carcinomas (cancer that begins in the cells on the surface of the ovary) or malignant germ cell tumors (cancer that begins in egg cells). In 2007, there will be an estimated 22,430 new cases and 15,280 deaths from ovarian cancer in the United States.

About Biocept

Biocept, an emerging biotechnology leader, engineers novel solutions that provide the foundation for a new class of diagnostics assays for prenatal and oncology applications. Its proprietary CEE(TM) Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics. This proprietary technology enables earlier, accurate, less invasive diagnoses. Isolation, purification and analysis of rare cells are managed within our state-of-the-art CLIA-accredited laboratory. Founded in 1997, Biocept is privately held and is based in San Diego, California.


'/>"/>
SOURCE Biocept
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... KEY FINDINGS North America ... market in 2016 and is expected to continue in ... a large number of surgical procedures that are taking ... in the patient temperature management market.) Patient warming and ... of blood during surgeries, lowering the risks of neurological ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
(Date:12/8/2016)... , 8 de dezembro de 2016  A Mederi Therapeutics Inc . ... um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and broadcast during ... at Wuhan Union Hospital ...
Breaking Medicine Technology:
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, cancer ... announced the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s ... possible. With this in mind, SIGVARIS has created a new line of anti-embolism ... bed rest and provide the benefits of graduated compression when transitioning from recovery ...
Breaking Medicine News(10 mins):